CU24555B1 - Combinación a dosis fija de paracetamol:amitriptilina - Google Patents

Combinación a dosis fija de paracetamol:amitriptilina

Info

Publication number
CU24555B1
CU24555B1 CU2018000037A CU20180037A CU24555B1 CU 24555 B1 CU24555 B1 CU 24555B1 CU 2018000037 A CU2018000037 A CU 2018000037A CU 20180037 A CU20180037 A CU 20180037A CU 24555 B1 CU24555 B1 CU 24555B1
Authority
CU
Cuba
Prior art keywords
paracetamol
amitriptyline
fixed
dose combination
synergy
Prior art date
Application number
CU2018000037A
Other languages
English (en)
Other versions
CU20180037A7 (es
Inventor
Fernández Pedro Gilberto Bárzaga
Menéndez Addis Bellma
La Paz Martín-Viaña Nilia De
Suárez Bárbara Beatriz Garrido
Cortezón Ania González
Yaquis Alejandro Saúl Padrón
Morales Rolando Perdomo
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2018000037A priority Critical patent/CU24555B1/es
Priority to PCT/CU2019/050002 priority patent/WO2019210889A1/es
Priority to CN201980029184.5A priority patent/CN112055585A/zh
Priority to CA3094488A priority patent/CA3094488A1/en
Priority to AU2019263876A priority patent/AU2019263876A1/en
Priority to JP2020560464A priority patent/JP2021521253A/ja
Priority to EP19727583.7A priority patent/EP3789020A1/en
Priority to US17/052,578 priority patent/US11590091B2/en
Priority to KR1020207034822A priority patent/KR20210013573A/ko
Priority to EA202092145A priority patent/EA202092145A1/ru
Priority to BR112020019985-0A priority patent/BR112020019985A2/pt
Publication of CU20180037A7 publication Critical patent/CU20180037A7/es
Priority to CL2020002632A priority patent/CL2020002632A1/es
Publication of CU24555B1 publication Critical patent/CU24555B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención describe una combinación farmacéutica a dosis fija de paracetamol y<br /> amitriptilina que muestran su sinergia para la reducción del dolor persistente inflamatorio y de la hipersensibilidad mecánica tras el daño neural, proporciones, seguridad y capacidad neuroprotectora.</p>
CU2018000037A 2018-05-03 2018-05-07 Combinación a dosis fija de paracetamol:amitriptilina CU24555B1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU2018000037A CU24555B1 (es) 2018-05-07 2018-05-07 Combinación a dosis fija de paracetamol:amitriptilina
JP2020560464A JP2021521253A (ja) 2018-05-03 2019-05-03 パラセタモール：アミトリプチリンの固定用量組成物および混合型がん性疼痛を治療するための方法
CN201980029184.5A CN112055585A (zh) 2018-05-03 2019-05-03 固定剂量的对乙酰氨基酚：阿米替林组合物和混合型癌症疼痛的治疗方法
CA3094488A CA3094488A1 (en) 2018-05-03 2019-05-03 Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
AU2019263876A AU2019263876A1 (en) 2018-05-03 2019-05-03 Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
PCT/CU2019/050002 WO2019210889A1 (es) 2018-05-03 2019-05-03 Composición a dosis fija de paracetamol:amitriptilina y método para el tratamiento del dolor mixto por cáncer
EP19727583.7A EP3789020A1 (en) 2018-05-07 2019-05-03 Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
US17/052,578 US11590091B2 (en) 2018-05-03 2019-05-03 Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
KR1020207034822A KR20210013573A (ko) 2018-05-03 2019-05-03 파라세타몰: 아미트리프틸린의 고정 용량 조성물 및 혼합 암 통증의 치료방법
EA202092145A EA202092145A1 (ru) 2018-05-07 2019-05-03 Композиция парацетамола: амитриптилина с фиксированной дозой и способ лечения смешанной раковой боли
BR112020019985-0A BR112020019985A2 (pt) 2018-05-03 2019-05-03 composição farmacêutica, uso de uma composição farmacêutica, e, kit
CL2020002632A CL2020002632A1 (es) 2018-05-07 2020-10-13 Composición a dosis fija de paracetamol:amitriptilina y método para el tratamiento del dolor mixto por cáncer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2018000037A CU24555B1 (es) 2018-05-07 2018-05-07 Combinación a dosis fija de paracetamol:amitriptilina

Publications (2)

Publication Number Publication Date
CU20180037A7 CU20180037A7 (es) 2019-12-03
CU24555B1 true CU24555B1 (es) 2021-12-08

Family

ID=66676966

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000037A CU24555B1 (es) 2018-05-03 2018-05-07 Combinación a dosis fija de paracetamol:amitriptilina

Country Status (12)

Country Link
US (1) US11590091B2 (es)
EP (1) EP3789020A1 (es)
JP (1) JP2021521253A (es)
KR (1) KR20210013573A (es)
CN (1) CN112055585A (es)
AU (1) AU2019263876A1 (es)
BR (1) BR112020019985A2 (es)
CA (1) CA3094488A1 (es)
CL (1) CL2020002632A1 (es)
CU (1) CU24555B1 (es)
EA (1) EA202092145A1 (es)
WO (1) WO2019210889A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176809A1 (en) 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
US20130189354A1 (en) * 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
BR112015013849A2 (pt) * 2012-12-21 2017-07-11 Sykehuset Soerlandet Hf terapia direcionada a egfr de distúrbios neurológicos e dor

Also Published As

Publication number Publication date
CL2020002632A1 (es) 2021-02-19
BR112020019985A2 (pt) 2021-01-26
US11590091B2 (en) 2023-02-28
KR20210013573A (ko) 2021-02-04
AU2019263876A1 (en) 2020-11-26
CN112055585A (zh) 2020-12-08
CA3094488A1 (en) 2019-11-07
US20210236440A1 (en) 2021-08-05
EA202092145A1 (ru) 2021-02-11
EP3789020A1 (en) 2021-03-10
WO2019210889A1 (es) 2019-11-07
JP2021521253A (ja) 2021-08-26
CU20180037A7 (es) 2019-12-03

Similar Documents

Publication Publication Date Title
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n&#39;- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016000556A1 (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
CL2017002229A1 (es) Inhibidores de bace1.
CU24555B1 (es) Combinación a dosis fija de paracetamol:amitriptilina
CY1122755T1 (el) Eξισορροπημενες απο αποψη φυσιολογιας ενεσιμες μορφοποιησεις φωσνετουπιταντης
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
PE20160245A1 (es) Composicion farmaceutica anti-tuberculosis estable en una forma de un comprimido dispersable que comprende granulos de isoniazid y granulos de rifapentina y su proceso de preparacion
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
NI202000017A (es) Composición farmacéutica para la prevención o el tratamiento de enfermedades cardiovasculares acompañadas por diabetes, que incluye amlodipino, losartán y rosuvastatina, y preparación compuesta que incluye los mismos
CL2020000120A1 (es) Composiciones farmacéuticas.
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.